Synonyms: ACT-179811 | ACT179811
Compound class:
Synthetic organic
Comment: Cadazolid (ACT-179811) is a quinolonyl-oxazolidinone (quinoxolidinone) antibacterial with Gram-positive activity. It targets the bacterial protein synthesis machinery by binding to the peptidyl transferase centre (PTC) of the ribosome [1].
|
|
No information available. |
Summary of Clinical Use |
Phase 3 trials for Clostridium difficile infection have been completed, but development was terminated as the drug did not achieve its primary endpoint of non-inferiority to vancomycin for clinical cure [2]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03105479 | Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD) | Phase 2/Phase 3 Interventional | Actelion | ||
NCT01987895 | Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea | Phase 3 Interventional | Actelion | 2 |